Sarepta Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Private, Public
- Established
- 1980-01-01
- Employees
- 1.3K
- Market Cap
- $13.4B
- Website
- http://www.sarepta.com
- Introduction
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)
- Conditions
- Limb Girdle Muscular Dystrophy
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05876780
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- Conditions
- Duchenne Muscular Dystrophy
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT05096221
- Locations
- 🇺🇸
Arkansas Children's, Little Rock, Arkansas, United States
🇺🇸UC San Diego Altman Clinical and Translational Research Institute, La Jolla, California, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- Conditions
- Muscular Dystrophy, Duchenne
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT04626674
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸University of California, Davis, Sacramento, California, United States
🇺🇸Washington University in St. Louis, Saint Louis, Missouri, United States
A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
- Conditions
- Limb-girdle Muscular Dystrophy
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 241
- Registration Number
- NCT04475926
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸Arkansas Children's, Little Rock, Arkansas, United States
🇺🇸University of California San Diego, La Jolla, California, United States
Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT04004065
- Locations
- 🇺🇸
University of California Davis Health, Sacramento, California, United States
🇺🇸Connecticut Children's, Farmington, Connecticut, United States
🇺🇸Northwest Florida Clinical Research Group, LLC, Gulf Breeze, Florida, United States
A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT03992430
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸Rare Disease Research, LLC, Atlanta, Georgia, United States
A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995)
- First Posted Date
- 2019-06-14
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03985878
- Locations
- 🇧🇪
UZ-Gent, Gent, Belgium
🇫🇷Hopital Trousseau, Bâtiment lemariey, Paris, France
🇮🇹Fondazione Policlinico Universitario Agostino Gemelli, UOC Neuropsichiatria Infantile, Rome, Italy
A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)
- Conditions
- Muscular Dystrophy, Duchenne
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT03769116
- Locations
- 🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03675126
- Locations
- 🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸NW FL Clinical Research Group, LLC, Gulf Breeze, Florida, United States
🇺🇸Center for Integrative Rare Disease Research (CIRDR), Atlanta, Georgia, United States
Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)
- Conditions
- Limb-Girdle Muscular Dystrophy, Type 2E
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03652259
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States